Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have earned an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $70.80.
A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Deciphera Pharmaceuticals from a "hold" rating to a "buy" rating and set a $54.00 price objective on the stock in a report on Friday, January 15th. Barclays cut their target price on shares of Deciphera Pharmaceuticals from $85.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 10th. SVB Leerink upgraded shares of Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $70.00 target price on the stock in a research report on Wednesday, February 10th. Finally, Credit Suisse Group assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Tuesday, March 30th. They set an "outperform" rating and a $78.00 target price on the stock.
NASDAQ:DCPH traded down $2.35 during trading hours on Tuesday, reaching $43.42. 20,745 shares of the company's stock were exchanged, compared to its average volume of 425,486. Deciphera Pharmaceuticals has a 1-year low of $39.42 and a 1-year high of $68.40. The company has a 50-day moving average of $45.07 and a 200 day moving average of $51.88. The firm has a market capitalization of $2.50 billion, a price-to-earnings ratio of -8.67 and a beta of 1.49.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Monday, February 8th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.16) by $0.06. The firm had revenue of $19.49 million for the quarter, compared to analyst estimates of $18.68 million. Equities research analysts forecast that Deciphera Pharmaceuticals will post -4.82 earnings per share for the current fiscal year.
In other Deciphera Pharmaceuticals news, Director Michael Douglas Taylor sold 8,000 shares of the company's stock in a transaction that occurred on Thursday, April 1st. The stock was sold at an average price of $45.57, for a total value of $364,560.00. Following the completion of the transaction, the director now owns 8,000 shares of the company's stock, valued at approximately $364,560. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director James Arthur Bristol sold 14,700 shares of the stock in a transaction that occurred on Monday, April 12th. The stock was sold at an average price of $43.84, for a total value of $644,448.00. Following the sale, the director now owns 14,700 shares in the company, valued at $644,448. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,000 shares of company stock worth $1,254,186. Company insiders own 7.02% of the company's stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Deciphera Pharmaceuticals by 4.6% in the 4th quarter. BlackRock Inc. now owns 3,409,858 shares of the company's stock worth $194,599,000 after purchasing an additional 150,286 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of Deciphera Pharmaceuticals by 35.8% during the fourth quarter. Wells Fargo & Company MN now owns 702,387 shares of the company's stock worth $40,085,000 after acquiring an additional 185,093 shares during the last quarter. Norges Bank purchased a new stake in shares of Deciphera Pharmaceuticals in the fourth quarter valued at $24,762,000. Hood River Capital Management LLC boosted its holdings in shares of Deciphera Pharmaceuticals by 69.3% in the 4th quarter. Hood River Capital Management LLC now owns 425,661 shares of the company's stock valued at $24,292,000 after buying an additional 174,280 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its holdings in shares of Deciphera Pharmaceuticals by 37.0% during the 4th quarter. UBS Asset Management Americas Inc. now owns 388,211 shares of the company's stock valued at $22,155,000 after purchasing an additional 104,822 shares in the last quarter. Institutional investors own 73.61% of the company's stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
Featured Story: Diluted Earnings Per Share
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Cost of Capital Explained7 Stocks to Watch When Student Debt Forgiveness Gets Passed
Now that the Biden administration is fully in charge, student debt forgiveness has moved to the front burner. Consider these numbers. There is an estimated $1.7 trillion in student debt. The average student carries approximately $30,000 in student loans.
If $10,000 of student debt were to be canceled, there are estimates that one-third of borrowers (between 15 million to 16.3 million) would become debt-free. Of course, if the number hits $50,000 as some lawmakers are suggesting the impact would even greater.
Putting aside personal thoughts on the wisdom of pursuing this path, it has the potential to unleash a substantial stimulus into the economy.
And as an investor, it’s fair to ask where that money would go. After all, there’s no harm in having investors profit from this stimulus as well.
A counter-argument is that the absence of one monthly payment may not provide enough money to make an impact. However, Senator Elizabeth Warren referred to the effect student loans have in preventing many in the millennial and Gen-Z generations from pursuing big picture life goals such as buying a house, starting a business, or starting a family.
With that in mind, we’ve put together this special presentation that looks at 7 stocks that are likely to benefit if borrowers are set free from the burden of student loans.
View the "7 Stocks to Watch When Student Debt Forgiveness Gets Passed"